Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

AT9283, 1-Cyclopropyl-3-(3-(5-(Morpholinomethyl)-1H-Benzo[d] Imidazole-2-yl)-1H-Pyrazol-4-yl) Urea, Inhibits Syk to Suppress Mast Cell-Mediated Allergic Response

  • Received : 2022.03.24
  • Accepted : 2022.06.23
  • Published : 2022.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Mast cells are an effector cell that plays a pivotal role in type I hypersensitive immune responses. Mast cells exist in connective tissues, such as skin and mucosal tissue, and contain granules which contain bioactive substances such as histamine and heparin in cells. The granules of mast cells are secreted by antigen stimulation to cause the type I allergic hypersensitivity. In addition, stimulated by antigen, mast cells synthesize and secrete various eicosanoids and cytokines. While AT9283 is known to have anticancer effects, the therapeutic effect of AT9283 on allergic disorders is completely unknown. In this study, it was found that AT9283 reversibly inhibited antigen-IgE binding-induced degranulation in mast cells (IC50, approx. 0.58 μM) and suppressed the secretion of the inflammatory cytokines IL-4 (IC50, approx. 0.09 μM) and TNF-α (IC50, approx. 0.19 μM). For a mechanism of mast cell inhibition, while not inhibiting Syk phosphorylation, AT9283 suppressed the activation of LAT, a downstream substrate protein of Syk, in a dose-dependent manner. As expected, AT9283 also inhibited the activation of PLCγ1 and Akt, downstream signaling molecules of Syk/LAT, and MAP kinases such as JNK, Erk1/2, and P38. In an in vitro protein tyrosine kinase assay, AT9283 directly inhibited Syk activity. Next, AT9283 dose-dependently inhibited passive cutaneous anaphylaxis (PCA), an IgE-mediated allergic acute response, in mice (ED50, approx. 34 mg/kg, p.o.). These findings suggest that AT9283 has potential to use as a new drug for alleviating the symptoms of IgE-mediated allergic disorders.

Keywords

Acknowledgement

This research was supported by the NRF grant (NRF-2017R1A2B4008572) funded by the Korea government.

References

  1. Akin, C. (2017) Mast cell activation syndromes. J. Allergy Clin. Immunol. 140, 349-355. https://doi.org/10.1016/j.jaci.2017.06.007
  2. Beaven, M. A. (2009) Our perception of the mast cell from Paul Ehrlich to now. Eur. J. Immunol. 39, 11-25. https://doi.org/10.1002/eji.200838899
  3. Da Costa, L., Scheers, E., Coluccia, A., Casulli, A., Roche, M., Di Giorgio, C., Neyts, J., Terme, T., Cirilli, R., La Regina, G., Silvestri, R., Mirabelli, C. and Vanelle, P. (2018) Structure-based drug design of potent pyrazole derivatives against Rhinovirus replication. J. Med. Chem. 61, 8402-8416. https://doi.org/10.1021/acs.jmedchem.8b00931
  4. Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M. and Tsai, M. (2005) Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749-786. https://doi.org/10.1146/annurev.immunol.21.120601.141025
  5. Galli, S. J. and Tsai, M. (2012) IgE and mast cells in allergic disease. Nat. Med. 18, 693-704. https://doi.org/10.1038/nm.2755
  6. Galli, S. J., Tsai, M. and Piliponsky, A. M. (2008) The development of allergic inflammation. Nature 454, 445-454. https://doi.org/10.1038/nature07204
  7. Hay, A. E., Murugesan, A., DiPasquale, A. M., Kouroukis, T., Sandhu, I., Kukreti, V., Bahlis, N. J., Lategan, J., Reece, D. E., Lyons, J. F., Sederias, J., Xu, H., Powers, J., Seymour, L. K. and Reiman, T. (2016) A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk. Lymphoma 57, 1463-1466. https://doi.org/10.3109/10428194.2015.1091927
  8. Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., Heathcote, M., Maman, S., Matthews, J. E., McMenamin, R. L., Navarro, E. F., O'Brien, M. A., O'Reilly, M., Rees, D. C., Reule, M., Tisi, D., Williams, G., Vinkovic, M. and Wyatt, P. G. (2009) Fragment-based discovery of the pyrazole-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 52, 379-388. https://doi.org/10.1021/jm800984v
  9. Karrouchi, K., Radi, S., Ramli, Y., Taoufik, J., Mabkhot, Y. N., Al-Aizari, F. A. and Ansar, M. (2018) Synthesis and pharmacologicalactivities of pyrazole derivatives: a review. Molecules 23, 134. https://doi.org/10.3390/molecules23010134
  10. Kawakami, T. and Galli, S. J. (2002) Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev. Immunol. 2, 773-786. https://doi.org/10.1038/nri914
  11. Kim, D. K., Kim, H. S., Kim, A. R., Jang, G. H., Kim, H. W., Park, Y. H., Kim, B., Park, Y. M., Beaven, M. A., Kim, Y. M. and Choi, W. S. (2013) The scaffold protein prohibitin is required for antigen-stimulated signaling in mast cells. Sci. Signal. 6, ra80.
  12. Krystel-Whittemore, M., Dileepan, K. N. and Wood, J. G. (2016) Mast cell: a multi-functional master cell. Front. Immunol. 6, 620.
  13. Lee, D., Park, Y. H., Lee, J. E., Kim, H. S., Min, K. Y., Jo, M. G., Kim, H. S., Choi, W. S. and Kim, Y. M. (2020) Dasatinib inhibits Lyn and Fyn Src-family kinases in mast cells to suppress type I hypersensitivity in mice. Biomol. Ther. (Seoul) 28, 456-464. https://doi.org/10.4062/biomolther.2020.013
  14. Lee, J. H., Kim, J. W., Kim, D. K., Kim, H. S., Park, H. J., Park, D. K., Kim, A. R., Kim, B., Beaven, M. A., Park, K. L., Kim, Y. M. and Choi, W. S. (2011) The Src family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice. J. Immunol. 187, 1807-1815. https://doi.org/10.4049/jimmunol.1100296
  15. Lee, J. H., Kim, J. W., Ko, N. Y., Mun, S. H., Her, E., Kim, B. K., Han, J. W., Lee, H. Y., Beaven, M. A., Kim, Y. M. and Choi, W. S. (2008) Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J. Allergy Clin. Immunol. 121, 1225-1231. https://doi.org/10.1016/j.jaci.2007.12.1160
  16. Lee, J. H., Kim, Y. M., Kim, N. W., Her, E., Kim, B. K., Kim, J. H., Ryu, S. H., Park, J. W., Seo, D. W., Han, J. W., Beaven, M. A. and Choi, W. S. (2006) Phospholipase D2 acts as an essential adaptor protein in the activation of Syk in antigen-stimulated mast cells. Blood 108, 956-964.
  17. Liu, G., Zhou, X., Chen, J. and Liu, F. (2018) Oral antihistamines alone vs in combination with leukotriene receptor antagonists for allergic rhinitis: a meta-analysis. Otolaryngol. Head Neck Surg. 158, 450-458. https://doi.org/10.1177/0194599817752624
  18. Matsubara, S., Li, G., Takeda, K., Loader, J. E., Pine, P., Masuda, E. S., Miyahara, N., Miyahara, S., Lucas, J. J., Dakhama, A. and Gelfand, E. W. (2006) Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 173, 56-63. https://doi.org/10.1164/rccm.200503-361OC
  19. Meltzer, E. O., Berkowitz, R. B. and Grossbard, E. B. (2005) An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115, 791-796. https://doi.org/10.1016/j.jaci.2005.01.040
  20. Nam, S. T., Kim, H. W., Kim, H. S., Park, Y. H., Lee, D., Lee, M. B., Min, K. Y., Kim, Y. M. and Choi, W. S. (2018) Furaltadone suppresses IgE-mediated allergic response through the inhibition of Lyn/Syk pathway in mast cells. Eur. J. Pharmacol. 828, 119-125. https://doi.org/10.1016/j.ejphar.2018.03.035
  21. Oettgen, H. C. (2016) Fifty years later: emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 137, 1631-1645. https://doi.org/10.1016/j.jaci.2016.04.009
  22. O'Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y. and Laurence, A. (2013) Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72, 111-115.
  23. Park, Y. H., Kim, H. W., Kim, H. S., Nam, S. T., Lee, D., Lee, M. B., Min, K. Y., Koo, J., Kim, S. J., Kim, Y. M., Kim, H. S. and Choi, W. S. (2019) An anti-cancer drug candidate CYC116 suppresses type I hypersensitive immune responses through the inhibition of Fyn kinase in mast cells. Biomol. Ther. (Seoul) 27, 311-317. https://doi.org/10.4062/biomolther.2018.148
  24. Pawankar, R., Canonica, G. W., Holgate, S. T., Lockey, R. F. and Blaiss, M. (2013) The WAO White Book on Allergy, p.11. World Allergy Organization, Milwaukee.
  25. Randall, K. L. and Hawkins, C. A. (2018) Antihistamines and allergy. Aust. Prescr. 41, 41-45.
  26. Rivera, J. and Gilfillan, A. M. (2006) Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 117, 1214-1226. https://doi.org/10.1016/j.jaci.2006.04.015
  27. Santo, L., Hideshima, T., Cirstea, D., Bandi, M., Nelson, E. A., Gorgun, G., Rodig, S., Vallet, S., Pozzi, S., Patel, K., Unitt, C., Squires, M., Hu, Y., Chauhan, D., Mahindra, A., Munshi, N. C., Anderson, K. C. and Raje, N. (2011) Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin. Cancer Res. 17, 3259-3271. https://doi.org/10.1158/1078-0432.CCR-10-3012
  28. Seow, C. J., Chue, S. C. and Wong, W. S. (2002) Piceatannol, a Sykselective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro. Eur. J.Pharmacol. 443, 189-196. https://doi.org/10.1016/S0014-2999(02)01534-0
  29. Shao, Y., Zhang, S., Zhang, Y. and Liu, Z. (2021) Recent advance of spleen tyrosine kinase in diseases and drugs. Int. Immunopharmacol. 90, 107168. https://doi.org/10.1016/j.intimp.2020.107168
  30. Siraganian, R. P., de Castro, R. O., Barbu, E. A. and Zhang, J. (2010) Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett. 584, 4933-4940. https://doi.org/10.1016/j.febslet.2010.08.006
  31. Tanaka, R., Squires, M, S., Kimura, S., Yokota, A., Nagao, R., Yamauchi, T., Takeuchi, M., Yao, H., Reule, M., Smyth, T., Lyons, J. F., Thompson, N. T., Ashihara, E., Ottmann, O. G. and Maekawa, T. (2010) Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 116, 2089-2095.
  32. Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2017) A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatr. Blood Cancer 64, e26351. https://doi.org/10.1002/pbc.26351
  33. Warrington, R., Silviu-Dan, F. and Wong, T. (2018) Drug allergy. Allergy Asthma Clin. Immunol. 14, 60. https://doi.org/10.1186/s13223-018-0289-y
  34. Yamamoto, N., Takeshita, K., Shichijo, M., Kokubo, T., Sato, M., Nakashima, K., Ishimori, M., Nagai, H., Li, Y. F., Yura, T. and Bacon, K. B. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 306, 1174-1181. https://doi.org/10.1124/jpet.103.052316